Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia.
(2025) British Journal of Haematology — Vol. 206, n° 1, p. 361-364 (2025)
Files
SansenPYBrJHaematol2024.pdf
Open Access - Adobe PDF
- 1.15 MB
Details
- Authors
Doyen, Chantal 
Bernard, Wivine Crochet, Gilles
- Abstract
- (en) Primary refractory disease for acute myeloid leukaemia (AML) is defined by the 2017 European LeukemiaNet (ELN) as the persistence of ≥5% blasts in bone marrow after two cycles of intensive chemotherapy or one cycle of high-dose cytarabine and can occur in 10%–40% of treated patients. The risk of failure after induction therapy containing daunorubicin and cytarabine (“3 + 7”) increases with the prognostic category of the AML and is associated with a poorer outcome. Classically, when facing a refractory situation, most centres proceed to another cycle of induction chemotherapy with an anthracycline-based regimen to achieve remission. Even though this strategy has proven effective, it significantly increases toxicity and the length of hospital stay. [...]
- Affiliations
Citations
Sansen, P.-Y., Graux, C., Sonet, A., André, M., Doyen, C., Collinge, E., Vellemans, H., Bernard, W., Crochet, G., Devreux, J., Depaus, J., Devalet, B., DESQUESNES, F., Pouplard, M., & Dachy, F. (2025). Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia. British Journal of Haematology, 206(1), 361-364. https://doi.org/10.1111/bjh.19906 (Original work published 2025)